Short Summary
Eunsung Global and HydraFacial jointly filed a motion asking the PTAB to keep their settlement agreement confidential and separate from the patent file, invoking 35 U.S.C. §317 and related regulations.
Detailed Summary
In IPR2025-00452 concerning U.S. Patent No. 12,053,607, petitioner Eunsung Global Corp. and patent owner HydraFacial LLC submitted a joint request to the Patent Trial and Appeal Board to treat their settlement agreement as business‑confidential information. Citing 35 U.S.C. §317 and 37 C.F.R. §42.74, they argue that the agreement contains sensitive details such as settlement amounts, private banking information, and legal obligations that should not be disclosed publicly. The parties seek to keep the agreement separate from the patent file and to make it available only upon a showing of good cause or to federal agencies.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Eunsung Global Corp. vs HydraFacial LLC et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Air Products and Chemicals, Inc.vsEVONIK OPERATIONS GMBH et al.
Air Products successfully convinced the PTAB to institute an IPR on 23 claims of EVONIK's patent, finding a reasonable likelihood that at least Claim 1 would be obvious over Ungerank and Scholz. The Board rejected arguments that the prior art taught away from the claimed invention.
Google LLCvsSecure Communication Technologies, LLC
Google successfully challenged Secure Communication Technologies' proximity‑beacon patent, with the PTAB finding all eight claims unpatentable based on multiple prior‑art references.
Election Systems & Software, LLCvsHart InterCivic, Inc.
The USPTO Board denied institution for PGR2025-00066 after reviewing the merits. The denial was based on the petitioner failing to demonstrate a reasonable likelihood of prevailing or that the claims were unpatentable.
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
The USPTO denied Abbott Laboratories’ request for Director Review of the institution decisions in three IPRs, leaving Miracor Medical’s patent 11,572,879 in place.
Meta Platforms, Inc.vsSitNet, LLC
Meta Platforms successfully challenged SitNet’s ’454 patent, leading the PTAB to find claims 1‑9 and 20 unpatentable and cancel claims 10‑19.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.